AK Medical Holdings Limited disclosed a fresh on-market repurchase of 1.00 million ordinary shares on 29 May 2026 at HK$5.97 per share, for a total consideration of HK$5.97 million. The transaction was executed on the Hong Kong Stock Exchange under the company’s existing share-buyback mandate approved on 18 June 2025.

Including this latest purchase, AK Medical has acquired 10.10 million shares for cancellation between 6 February and 29 May 2026. The cumulative volume represents approximately 8.99% of the 112.27 million shares authorised under the mandate and equates to about 0.90% of the company’s 1.12 billion issued shares. Total cash deployed across all buys reached roughly HK$62.32 million, implying an average repurchase price of HK$6.17 per share.

All repurchased shares remain uncancelled as at 29 May 2026, leaving the company’s issued share capital unchanged at 1.12 billion shares. Under Hong Kong listing rules, AK Medical is subject to a moratorium on issuing new shares until 28 June 2026.

The board confirmed that every repurchase complied with Main Board Listing Rules and that no material changes have occurred to the repurchase mandate’s explanatory statement previously filed with the Exchange.